Table 3.
HIV nPEP antiviral medications doses.
| (1) If the patient is ≥18 years of age with a negative urine pregnancy test, normal liver function and complete blood count tests, and a creatinine clearance of ≥50 mL/minute: | |
| Emtricitabine/tenofovir: one tablet by mouth every day for twenty-eight days | |
| PLUS | |
| Lopinavir/ritonivir: two tablets by mouth twice daily for twenty-eight days | |
|
| |
| (2) If the patient is ≥12 and <18 years of age or is pregnant at any age with normal liver function and complete blood count tests and a creatinine clearance of ≥50 mL/minute: | |
| Lamivudine/zidovudine: one tablet by mouth twice daily for twenty-eight days | |
| PLUS | |
| Lopinavir/ritonivir: two tablets by mouth twice daily for twenty-eight days | |
|
| |
| (3) Patients with Hepatitis B or C may be given emtricitabine/tenofovir and lopinavir/ritonivir as long as their baseline liver function tests are normal. | |
|
| |
| (4) Patients with baseline abnormal renal function should not receive emtricitabine/tenofovir. Instead, they should be started on lopinavir/ritonavir (as above) plus lamivudine/zidovudine with dosing adjustments listed below. | |
|
| |
| Dosage adjustments for patients ≥12 years of age with CrCL <50 mL/minute | |
| CrCL | Renal dosage |
|
| |
| 30–49 mL/minute | Lamivudine 150 mg tablet QDay zidovudine 300 mg tablet BID |
| 15–29 mL/minute | Lamivudine oral solution 100 mg/10 mL QDay zidovudine 300 mg tablet BID |
| 5–14 mL/minute | Lamivudine oral solution 50 mg/ 5mL QDay zidovudine 300 mg tablet BID |
| <5 mL/minute | Lamivudine oral solution 25 mg/2.5 mL QDayzidovudine 300 mg tablet QDay |
Adapted from CDC MMWR 2005 [1].